Oxybutynin transdermal (Oxytrol) for overactive bladder.
D000279:Administration, Cutaneous; D000284:Administration, Oral; D001559:Benzhydryl Compounds / Q000008:administration & dosage / Q000009:adverse effects; D003408:Cresols / Q000008:administration & dosage / Q000009:adverse effects; D003692:Delayed-Action Preparations; D006801:Humans; D008333:Mandelic Acids / Q000008:administration & dosage* / Q000009:adverse effects; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate; D001745:Urinary Bladder Diseases / Q000188:drug therapy*; D014987:Xerostomia / Q000139:chemically induced
D001559:Benzhydryl Compounds; D003408:Cresols; D003692:Delayed-Action Preparations; D008333:Mandelic Acids; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate; C005419:oxybutynin